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Abstract
Celiac disease (CeD) is an immune-mediated enteropathy with a strong genetic component where the main environmental
trigger is dietary gluten, and currently a correct diagnosis of the disease is impossible if gluten-free diet (GFD) has already
been started. We hypothesized that merging different levels of genomic information through Mendelian randomization (MR)
could help discover genetic biomarkers useful for CeD diagnosis. MR was performed using public databases of expression
quantitative trait loci (QTL) and methylation QTL as exposures and the largest CeD genome-wide association study
conducted to date as the outcome, in order to identify potential causal genes. As a result, we identified UBE2L3, an ubiquitin
ligase located in a CeD-associated region. We interrogated the expression of UBE2L3 in an independent data set of peripheral
blood mononuclear cells (PBMCs) and found that its expression is altered in CeD patients on GFD when compared to
non-celiac controls. The relative expression of UBE2L3 isoforms predicts CeD with 100% specificity and sensitivity and could
be used as a diagnostic marker, especially in the absence of gluten consumption. This approach could be applicable to other
diseases where diagnosis of asymptomatic patients can be complicated.
Introduction
In the last decade, genome-wide association studies (GWAS)
have identified thousands of disease-associated suscepti-
bility variants whose etiological role remains elusive (1).
In this context, Mendelian randomization (MR) approaches
that confront summary statistics from GWAS with results
from expression quantitative trait loci (eQTL) studies have
proven useful to detect pleiotropic associations between gene
expression and particular traits and also to prioritize genes
under GWAS peaks (2,3). More recently, methylation data
have been used to propose a plausible mechanism whereby
several single nucleotide polymorphism (SNP)–disease associ-
ations are mediated by transcription regulation through DNA
methylation (4).
Celiac disease (CeD) is a common, immune-mediated
enteropathy where alleles encoding human leukocyte antigen
(HLA)-DQ2 and -DQ8 molecules account for 40% of disease
heritability (5). The main environmental trigger of the disorder
is dietary gluten, and being on a gluten-containing diet is
necessary for a correct diagnosis of the disease. However,
self-reported wheat sensitivity is a rising global phenomenon
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that is changing the consumption and eating habits and
reaches 12.2% and 13% of the general population in Western
countries like Italy and the United Kingdom, respectively (6).
As a consequence, many will start gluten-free diet (GFD) before
medical consultation, therefore hindering the diagnosis of CeD.
In those cases, gluten challenge prior to duodenal endoscopy is
the only available diagnostic protocol, albeit often non-effective
and always invasive and troublesome (7). Other common
disorders also present similar diagnostic challenges, like severe
reactions during provocation with the causal compound in drug
allergy (8) or difficulties to assess airflow limitation in childhood
asthma (9). A genetic, constitutive biomarker present also when
the disease-triggering insult is absent would be extremely useful
for the diagnosis of these type of conditions.
We hypothesized that the overlapping results from methy-
lation and expression-based MR analyses could not only clarify
mechanisms underlying SNP–disease associations (4) but also
provide genetic biomarkers that could be useful in the diagnosis
of latent diseases. Here, we perform the first MR analysis in
CeD using publicly available GWAS, eQTL and methylation QTL
(mQTL) data and interrogate the resulting candidates in inde-
pendent expression databases to test their diagnostic potential.
Results
We used MR to infer causal relationships between an exposure
(e.g. altered gene expression or methylation) and an outcome
(CeD). Since SNP alleles are randomly assigned to each individ-
ual, MR assumes that if an exposure is implicated in disease
etiology, then the genetic variants associated with the exposure
(eQTL/mQTL SNPs) will be associated with disease risk. Thus,
confronting eQTL/mQTL (SNP–gene expression/methylation)
and GWAS (SNP–disease) results, we can select those genes
whose expression or methylation is altered by a SNP allele that
in turn has been shown to increase the risk of developing the
disease.
Therefore, in order to identify the causative genes driving
GWAS associations, we first ran the summary-data-based MR
(SMR) software (https://cnsgenomics.com/software/smr) (2)
using results from the to-date largest CeD GWAS (9451 cases and
16434 controls) (5) and from the Consortium for the Architecture
of Gene Expression (CAGE) eQTL database (P<1e-5) (10) (namely,
genotype to transcription approach or G2T). We also ran SMR
with the top blood mQTLs (P<1e-5; n=1366) available at the
SMR website (11) to test the association of DNA methylation
with CeD and detect possible effects of SNPs on methylation
(G2M) or of methylation on the expression of nearby genes (M2T)
and finally considered the intersection of these three analyses
(G2T∩G2M∩M2T) (Fig. 1A).
The G2T analysis using the CAGE blood eQTL database
identified 8 SNPs associated with the expression levels of
10 different Illumina probes representing 8 genes, namely
CD247, UBE2L3, MMEL1, ANXA6, TAGAP, PLEK, SIRT1 and
PARK7 (Table 1; Fig. 1B; Supplementary Material, Table 1.1).
The G2M analysis resulted in 51 cytosine-phosphate-guanine
(CpG) sites pleiotropically related to 27 CeD-associated SNPs
(Supplementary Material, Table 1.2). On the other hand, the M2T
analysis considered methylation of nearby CpG sites to mediate
the association between a given SNP and the expression of a
particular gene and therefore identified 22824 CpG–SNP pairs
(Supplementary Material, Table 2) whose pleiotropic association
could drive the variation at expression level locally.
We then considered the overlap between the three different
studies (G2T∩G2M∩M2T) since it has been suggested that such
Figure 1. (A) Schematic representation of the SMR approach. (B) Manhattan plot
representing the −log10 P-values of the G2T-SMR analysis using the CAGE eQTL
database. The genomic location of the resulting SNPs are shown in the x-axis
while the −log10 P-values of the G2T-SMR analysis are depicted in the y-axis.
Those SNPs that do not pass the HEIDI cut-off have been excluded from the
plot. The eight unique SNPs resulting from the G2T analysis are highlighted in
red and marked with closest gene names. When two dots are plotted for the
same genomic location, this means that two forms/probes of the same gene
have been identified as mediators of the given SNP and CeD. When listed as
G2T∩G2M∩M2T overlapping hits in the discovery data set, gene names and dots
have been underlined.
an approach could provide information not only on the most
relevant variation associated with complex traits but also on
the putative mechanisms involved. As a result, we identified 10
SNP–gene pairs (SupplementaryMaterial, Table 1.3), namely four
different CpG sitesmediating the association between rs3748816
on chromosome 1 and themetalloendopeptidaseMMEL1 and six
CpGs related to rs5754217 on chromosome 22 and the ubiquitin
ligase UBE2L3. In particular, three out of the six later CpG sites
were located close to the UBE2L3 promoter, while the rest spread
across the 5′UTR of the gene (Fig. 2).
The rs5754217–UBE2L3 pleiotropic association and therefore
the putative mediation of UBE2L3 expression levels between
the SNP and CeD was further confirmed in the GTEx blood
eQTL database (Supplementary Material, Table 3.1) and in
the eQTL-Gen database (Supplementary Material, Table 3.2),
with a P=4.09e-05 and a P=7.68e-07, respectively. Additionally,
when the M2T analysis was rerun with each of these two
eQTL databases, the G2T∩G2M∩M2T overlap revealed that the
rs5754217–UBE2L3–CeD association was again apparently medi-
ated by themethylation of adjacent CpGs. Interestingly, although
other SNP–gene pairs were identified in the replication, UBE2L3
was the only hit resulting from the G2T∩G2M∩M2T analysis
common to all three data sets studied (Supplementary Material,
Table 3). In contrast, the G2T analysis performed in the small
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Table 1. Summarized results of the G2T approach in whole-blood CAGE eQTLs. b refers to the beta-effect size or log (odds ratio) of the allele
frequency/expression related to each SNP in each data set
probeID Gene SNP chr bp b_GWAS p_GWAS b_eQTL p_eQTL b_SMR p_SMR
ILMN_1676924 CD247 rs864537 1 167411384 −0.141 1.01E-07 0.344 6.22E-34 −0.411 1.08E-06
ILMN_1677877 UBE2L3 rs5754217 22 21939675 0.152 6.92E-07 0.917 6.88E-156 0.166 1.13E-06
ILMN_2377669 CD247 rs864537 1 167411384 −0.141 1.01E-07 0.320 1.96E-29 −0.441 1.48E-06
ILMN_1718488 MMEL1 rs3748816 1 2526746 −0.136 4.93E-07 −0.380 7.84E-41 0.359 2.51E-06
ILMN_2326591 ANXA6 rs2303038 5 150535013 0.134 1.10E-05 0.530 4.47E-59 0.252 1.88E-05
ILMN_2333774 TAGAP rs9295089 6 159463964 0.187 1.66E-06 −0.338 2.47E-16 −0.554 3.53E-05
ILMN_1795762 PLEK rs3816281 2 68607947 −0.124 2.85E-05 0.598 3.64E-77 −0.207 4.49E-05
ILMN_1676408 TAGAP rs9295089 6 159463964 0.187 1.66E-06 −0.302 1.78E-13 −0.620 5.92E-05
ILMN_1739083 SIRT1 rs17712705 10 69623271 0.112 3.47E-05 0.456 4.24E-54 0.245 6.28E-05
ILMN_1744713 PARK7 rs12727642 1 8046672 0.134 3.06E-05 0.428 2.45E-34 0.312 7.44E-05
Figure 2. UBE2L3-rs5754217 region onChr22.The y-axis in the upper panel shows
the logarithmic P-values of both the eQTL and GWAS data sets, as well as the one
resulting from the G2T-SMR analysis performed with the CAGEwhole-blood data
set. Diamonds and golden arrows represent genes. Particularly, empty diamonds
represent genes in the region whose P-values in the G2T-SMR approach did
not reach statistical significance, while the maroon diamond represents the
statistically significant hit (UBE2L3). Numbers 4 and 5 above the isoform 2
indicate the UBE2L3 fourth and fifth exons, respectively.
intestine eQTLs of the GTEx database did not reveal significant
results, suggesting the cell type-specificity of our finding.
Regarding the expression analysis, two different probes
interrogate UBE2L3 expression in the celiac peripheral blood
mononuclear cell (PBMC)microarray.One is on an exon common
to all isoforms (ILMN_1677877, here denoted as UBE2L3.1) and
the other is exclusive of an alternative, non-coding transcript
(ILMN_1796830 or UBE2L3.2) (Figure 2). Both probes showed a
dramatic, albeit opposite alteration of UBE2L3 expression in CeD
(P<1e-4) (Fig. 3A). Interestingly, theminor allele of the rs5754217
SNP is the risk allele in CeD and is positively correlated with
expression, a result that is consistent with the upregulation of
the coding forms of UBE2L3. However, the expression of the
coding isoforms shows strong negative correlation with the
expression levels of the non-coding isoform 2, here represented
as UBE2L3.2 (Fig. 3B).
Additionally, the relative expression score of UBE2L3was able
to perfectly distinguish GFD–CeD patients from controls, at a
relative expression threshold of 1.09 (Fig. 3C). This resulted in a
receiver operating characteristic (ROC) curve with an area under
the curve (AUC) value of 1 and therefore 100% specificity and
sensitivity in the discrimination capacity of CeD patients in GFD,
while each UBE2L3 exons independently showed less prediction
potential (AUC of 0.997 and 0.997, respectively) (Fig. 4). Interest-
ingly, none of the probes available to report the UBE2L3 expres-
sion in the Affymetrix array of the CD and UC samples was able
to distinguish patients from controls, showing AUC values rang-
ing between 0.528–0.699 and 0.452–0.752, respectively (Fig. 4).
Finally, we interrogated the rest of the candidate genes
resulting from the G2T∩G2M∩M2T approaches conducted
separately in each of the discovery and replication eQTL data
sets in the celiac PBMC expression study (Supplementary
Material, File 1). In summary, CD247 and MMEL1 did not show
any differential expression when PBMCs from CeD patients on
GFD and from controls were compared. In contrast, some of
the probes representing AHSA2, BACH2, CCDC116 and CDC73
were significantly altered in patients, especially the only
probe covering AHSA2 (ILMN_1798308, P=1.63e-05) and one
of the BACH2 probes (ILMN_1670695, P=8.15e-04), although an
expression cutoff capable of distinguishing cases from controls
could not be established in any of the cases (Supplementary
Material, File 1).
Discussion
As far as we know, the number of published MR analyses aiming
to discover clinically relevant gene expression signatures is lim-
ited. For example, a very interesting study proposed expression-
SMR as a valuable tool for the discovery of functionally relevant
genes in several diseases (12) but did not test the diagnos-
tic potential of the identified candidates in independent gene
expression data sets. Here, we demonstrate that the genetic
and epigenetic dysregulation prioritized by MR can be of clinical
interest. Furthermore, we propose that when gene expression
and methylation of nearby CpG sites are related to the same
disease-associated variants and also between each other, one
is more likely to identify genes whose expression is selectively
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Figure 3. Results of the expression analysis. (A) Expression of UBE2L3 isoforms and ASHA2 in PBMCs of celiac patients on GFD. Gray dots and black squares represent
non-celiac controls and CeD patients on GFD, respectively. (B) Pearson correlation across the entire sample set between the expression levels of the isoforms of UBE2L3
reported by the two different Illumina assays. (C) Relative expression score of UBE2L3. Gray dots and black squares represent non-celiac controls and CeD patients on
GFD, respectively.
altered in a specific disease, since different information layers
regulating gene expression are affected specifically in patients.
We present the first MR analysis performed in CeD, and we
manage to identify a set of SNPs whose association with CeD
could be mediated by the expression of genes in cis and by
the methylation levels of nearby CpG positions. For example,
CD247, although not altered in patients on GFD, participates in
the T-helper 17 cell-signaling pathway and has been described
to be diminished in the mucosa of active CeD individuals (13).
On its side, AHSA2 is remarkably downregulated in PBMCs from
CeD patients on GFD and has previously been shown to be sub-
jected to CeD-associated SNP regulation in the thymus (14), and
BACH2, an important immune regulator known to be repressed
in CD4+ T cells in active CeD, remains partially silenced after
GFD treatment (15). On the other hand, although MMEL1 is not
altered in CeD patients on GFD, it is worthy to mention that in a
pediatric CeD cohort, the same rs3748816-cg21209485 binomial
in the MMEL1 gene body that is described here was one of the
very few mQTLs found to be common to both the epithelial
and immune fractions of the duodenal mucosa (16). Altogether,
these results strongly support themediation of DNAmethylation
in the GWAS-association peak on chromosome 1 that includes
MMEL1.
UBE2L3 is an ubiquitin ligase that had been previously pri-
oritized in CeD (17), although within a long list of candidate
genes. Recently, UBE2L3 has been described to be relevant in
lupus erythematosus (LE) after merging GWAS and methylome
results (18). Interestingly, the CpG site that seems to mediate
this LE association is an mQTL of rs5754217, the same SNP
that results from our MR application in CeD, supporting the
idea of a common regulatory mechanism in both autoimmune
disorders. Additionally, it has been shown that the NF-κB path-
way, an inflammatory route that is exacerbated in CeD (19),
is very sensitive to the expression of UBE2L3, which in turn is
very upregulated in LE plasma cells (20). Altogether, these facts
suggest that UBE2L3 could be a relevant functional player in CeD
as well as in other immune-mediated diseases.
Last but not least, the relative expression of UBE2L3 isoforms
described here could be an important discovery for the diagnosis
of CeD, mainly in individuals on self-imposed GFD. Moreover,
the diagnostic potential of UBE2L3 seems to be CeD specific,
since it does not work efficiently in other immune-mediated
conditions of the gut. As previously stated, new eating habits
are complicating enormously the diagnosis of CeD (6). This diag-
nostic challenge is of general interest among gastroenterologists
and has encouraged relevant studies, such as a recent work that
proposes HLA-DQ-gluten tetramers as blood biomarkers that
could help distinguish CeD from non-CeD individuals in the
absence of gluten consumption, with AUC values around 0.96
(21). The UBE2L3 expression score presented here has an AUC
of 1 and is a potential diagnostic marker for CeD in PBMCs from
individuals on GFD that, nevertheless, will have to be validated
in prospective studies. Our approach is less time consuming
and more easily adaptable to a clinical setting since it could be
implemented through a simple polymerase chain reaction (PCR)-
based expression analysis. However, in case UBE2L3 is confirmed
as a marker of CeD in peripheral blood, it should always be used
together with other determinations such as HLA genotyping.
In conclusion, our strategy could be applicable to other disor-
ders in which diagnosis in the absence of the trigger driving the
acute phase of the disease is challenging and is a good demon-
stration of the potential translation of the results of genomic
studies, and particularly MR, to the routine clinical practice.
However, the MR strategy itself is necessary but not sufficient to
discover biomarkers, and follow-up expression analyses in fully
independent data sets should be performed in order to fine-tune
the pipeline.
Material and Methods
SMR analyses
In general, we used the default parameters suggested by the
developers of the SMR software, including the application of
the heterogeneity in dependent instruments (HEIDI) test, that
resulted in filtering out those hits that arouse from significant
linkage with pleiotropically associated variants (linkage disequi-
librium cutoff of P=0.05 in the HEIDI test, as suggested by SMR).
More specifically, the software proposes a global test to account
for linkage disequilibrium structure between SNPs by reading
individual-level SNP genotype data from a reference sample. In
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/18/3037/5498731 by U
niversidad del Pais Vasco user on 10 January 2020
Human Molecular Genetics, 2019, Vol. 28, No. 18 3041
Figure 4. ROC curves with PBMC expression levels of the candidate genes as
binary classifiers in CeD, CD and UC.
our case, we uploaded not only the summary statistics of the
celiac GWAS but also the complete data set in PLINK format.
We considered significant pleiotropic associations and kept
for the subsequent analytical steps those hits that fulfilled the
following criteria: an empirical P<1e-4 and P>0.05 in the SMR
and HEIDI tests, respectively, in the G2T and G2M analyses
and an empirical P<1e-7 for M2T, given the high number of
multiple comparisons performed in the latter case. If adjacent
SNP informationwas not available to compute the HEIDI P-value,
we kept the hit and proceeded to the next step, because since
different genotyping technologies have been used to generate
the different databases, excluding hits for which HEIDI cannot
be computed in one of them often means removing from fur-
ther consideration interesting SNPs that are replicated and pass
the HEIDI cutoff elsewhere. Additionally, we plotted the UBE2L3
adjacent region on chromosome 22 by using the SMRLocusPlot
function of the source code available at the SMR website, with a
plot window of 1000 kb.
Replication using GTEx blood and intestine eQTLs and
the eQTL-Gen database
Wealso ran the SMR software using results from the celiac GWAS
and from the GTEx eQTL (P<1e-5) database (22). In particular,
we used the whole blood eQTLs (n=122) for the replication of
the findings of the discovery set and the small intestine eQTLs
(n=369) to conduct a sensitivity analysis with the final aim of
assessing heterogeneity of effects across the main tissues rele-
vant to CeD. Additionally, we rerun the analysis in the eQTL-Gen
database, where blood of 31 684 individuals has recently been
studied (23). For both GTEx and eQTL-Gen, we kept the same
criteria used for the CAGE eQTL analysis, namely an empirical
SMR threshold of P<1e-4 for the G2T analysis, an empirical SMR
threshold of P<1e-7 for the M2T analysis, as well as P>0.05 in
the HEIDI test in both cases.
Expression analysis
We interrogated UBE2L3, the only candidate gene resulting
from the G2T∩G2M∩M2T approach and replicated in the two
additional eQTL data sets, in two fully independent expression
microarray experiments performed in PBMCs available in Gene
Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/): an
Illumina HumanHT-12 V4.0 expression Beadchip analysis of
17 CeD patients on GFD and 20 controls (GSE113469) (24)
and an Affymetrix Human Genome U133A Array study of
42 controls and 59 Crohn’s disease and 26 ulcerative colitis
patients (GSE3365) (25). Comparisons were performed using
Mann–Whitney U tests, and ROC curves were constructed using
the expression levels of the candidates as binary classifiers.
The UBE2L3 relative expression score was calculated from
the intensity units of the two UBE2L3 probes available at
the celiac PBMC study and the GAPDH housekeeping gene
with this formula: 2∧((UBE2L3.1−UBE2L3.2)/GAPDH), where
UBE2L3.1 = ILMN_1677877 Illumina probe (mapping to exon 5,
common to all UBE2L3 variants); UBE2L3.2 = ILMN_1796830
Illumina probe (mapping to exon 4, exclusive for theUBE2L3non-
coding variant 2) and GAPDH= ILMN_1343295 Illumina probe.
We decided to test the full set of genes resulting from
the G2T∩G2M∩M2T approach performed separately in each of
the discovery and replication eQTL data sets, with the final
aim of ascertaining whether there was any other biomarker
among them. In particular, we interrogated all the probes
available for AHSA2 (ILMN_1798308), BACH2 (ILMN_1659943,
ILMN_2058468 and ILMN_1670695), CCDC116 (ILMN_1795085),
CD247 (ILMN_2377669 and ILMN_1676924),CDC73 (ILMN_1730745
and ILMN_1701614) and MMEL1 (ILMN_2151241 and ILMN_17184
88) in the same PBMC expression data set of celiac patients on
GFD and controls (GSE113469). We performed unpaired, two-
tailed T-tests in Microsoft Excel version 14.0.7232.5000 (32 bits)
to test for differential expression.
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